Pancreatic insufficiency in Cystic Fibrosis.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Cystic Fibrosis

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jcf.2017.06.011PMID 28986019
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cystic Fibrosis-Related Diabetes

  2024cited by this paper
• UvA-DARE ( Digital Academic Repository ) Children with severe acute malnutrition

  2018cited by this paper
• Differences in Outcomes between Early and Late Diagnosis of Cystic Fibrosis in the Newborn Screening Era

  2017cited by this paper
• Increased Fat Absorption From Enteral Formula Through an In-line Digestive Cartridge in Patients With Cystic Fibrosis

  2017cited by this paper
• Practical guide to exocrine pancreatic insufficiency – Breaking the myths

  2017cited by this paper
• Secretin-stimulated MRI assessment of exocrine pancreatic function in patients with cystic fibrosis and healthy controls

  2017cited by this paper
• Diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis: 13C-Mixed Triglyceride Breath Test versus Fecal Elastase.

  2017cited by this paper
• Assessment of intestinal malabsorption.

  2016cited by this paper
• Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis

  2016cited by this paper
• Under Utilization of Pancreas Transplants in Cystic Fibrosis Recipients in the United Network Organ Sharing (UNOS) Data 1987–2014

  2016cited by this paper
• Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines.

  2016cited by this paper
• Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial.

  2016cited by this paper
• Drug therapies for reducing gastric acidity in people with cystic fibrosis.

  2016cited by this paper
• Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.

  2016cited by this paper
• ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis.

  2016influential reference
• Malabsorption blood test: Assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency

  2015cited by this paper
• Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis.

  2015cited by this paper
• Insulin secretion abnormalities in exocrine pancreatic sufficient cystic fibrosis patients.

  2015influential reference
• Diagnostic accuracy of secretin-stimulated ultrasonography of the pancreas assessing exocrine pancreatic failure in cystic fibrosis and chronic pancreatitis

  2015cited by this paper
• Diagnostic Accuracy of a Short Endoscopic Secretin Test in Patients With Cystic Fibrosis

  2015cited by this paper
• Pancreatic Enzyme Replacement Therapy and Coefficient of Fat Absorption in Children and Adolescents With Cystic Fibrosis

  2015cited by this paper
• CFTR, bicarbonate, and the pathophysiology of cystic fibrosis

  2015cited by this paper
• Drug therapies for reducing gastric acidity in people with cystic fibrosis.

  2014cited by this paper
• Vitamin B12 Status in Children With Cystic Fibrosis and Pancreatic Insufficiency

  2014cited by this paper
• Fat-soluble vitamin deficiency in children and adolescents with cystic fibrosis

  2014cited by this paper
• Cystic Fibrosis Related Diabetes

  2014cited by this paper
• Evidence for a Causal Relationship Between Early Exocrine Pancreatic Disease and Cystic Fibrosis–Related Diabetes: A Mendelian Randomization Study

  2014cited by this paper
• Simultaneous liver-pancreas transplantation for cystic fibrosis-related liver disease: a multicenter experience.

  2014cited by this paper
• Cigarette smoking impairs pancreatic duct cell bicarbonate secretion.

  2013cited by this paper
• Update on cystic fibrosis-related diabetes.

  2013cited by this paper
• Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis

  2013cited by this paper
• Evolution of pancreatic function during the first year in infants with cystic fibrosis.

  2013cited by this paper
• Intestinal pH and Gastrointestinal Transit Profiles in Cystic Fibrosis Patients Measured by Wireless Motility Capsule

  2013cited by this paper
• Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function.

  2013cited by this paper
• Nutritional intervention in patients with Cystic Fibrosis: a systematic review.

  2013cited by this paper
• Liprotamase Long-term Safety and Support of Nutritional Status in Pancreatic-insufficient Cystic Fibrosis

  2012cited by this paper
• Pancreatic damage in fetal and newborn cystic fibrosis pigs involves the activation of inflammatory and remodeling pathways.

  2012cited by this paper
• An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation.

  2012cited by this paper
• Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening

  2011cited by this paper
• Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis.

  2011cited by this paper
• Partial Pancreatic Resection for Pancreatic Malignancy Is Associated with Sustained Pancreatic Exocrine Failure and Reduced Quality of Life: A Prospective Study

  2011cited by this paper
• An Activated Immune and Inflammatory Response Targets the Pancreas of Newborn Pigs with Cystic Fibrosis

  2011cited by this paper
• Clinical care guidelines for cystic fibrosis-related diabetes:a position statement of the Americal Diabetess Association and a clinical practice guideline of the Cystic Fibrosis Foundation ,endorsed by the pedistric Endocrine Society

  2011cited by this paper
• Acid steatocrit determination is not helpful in cystic fibrosis patients without or with mild steatorrhea

  2010cited by this paper
• Update on cystic fibrosis-related diabetes

  2010cited by this paper
• Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes

  2010cited by this paper
• Cystic Fibrosis–Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality

  2009cited by this paper
• Effect of calcium from dairy and dietary supplements on faecal fat excretion: a meta‐analysis of randomized controlled trials

  2009cited by this paper
• Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

  2009cited by this paper
• Tests of pancreatic exocrine function - clinical significance in pancreatic and non-pancreatic disorders.

  2009cited by this paper
• The Endoscopic Pancreatic Function Test

  2009cited by this paper
• Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.

  2009cited by this paper
• A prospective crossover study comparing secretin-stimulated endoscopic and Dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis.

  2008cited by this paper
• Cystic fibrosis and estrogens: a perfect storm.

  2008cited by this paper
• Pancreatic Enzyme Pharmacotherapy

  2007cited by this paper
• Comparison of Monoclonal and Polyclonal ELISAs for Fecal Elastase in Patients With Cystic Fibrosis and Pancreatic Insufficiency

  2007cited by this paper
• A Randomized Crossover Study of Secretin-Stimulated Endoscopic and Dreiling Tube Pancreatic Function Test Methods in Healthy Subjects

  2006cited by this paper
• Human pancreatic exocrine response to nutrients in health and disease

  2005cited by this paper
• Early Decline of Pancreatic Function in Cystic Fibrosis Patients with Class 1 or 2 CFTR Mutations

  2005cited by this paper
• Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized, three‐way crossover study

  2005cited by this paper
• Pancreatic enzyme therapy and clinical outcomes in patients with cystic fibrosis.

  2005cited by this paper
• Duodenal pH in cystic fibrosis and its relationship to fat malabsorption

  2005cited by this paper
• Gastrointestinal outcomes and confounders in cystic fibrosis.

  2005cited by this paper
• Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas

  2005cited by this paper
• Cystic fibrosis adult care: consensus conference report.

  2004cited by this paper
• Percutaneous endoscopic gastrostomy in cystic fibrosis: patient acceptance and effect of overnight tube feeding on nutritional status.

  2004cited by this paper
• Longitudinal Follow-Up of Exocrine Pancreatic Function in Pancreatic Sufficient Cystic Fibrosis Patients Using the Fecal Elastase-1 Test

  2003cited by this paper
• Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes

  2003cited by this paper
• How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease?

  2002cited by this paper
• Prospective, Long-Term Study of Fat-soluble Vitamin Status in Children with Cystic Fibrosis Identified by Newborn Screen

  2000cited by this paper
• Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen.

  1999cited by this paper
• Effects of a proton‐pump inhibitor in cystic fibrosis

  1998cited by this paper
• Pathology of pancreatic and intestinal disorders in cystic fibrosis

  1998influential reference
• High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis.

  1997cited by this paper
• Ranitidine and Omeprazole as Adjuvant Therapy to Pancrelipase to Improve Fat Absorption in Patients With Cystic Fibrosis

  1996cited by this paper
• Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee.

  1995cited by this paper
• Cystic fibrosis-associated colitis and fibrosing colonopathy.

  1995cited by this paper
• Vitamin A.

  1995cited by this paper
• Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes.

  1994cited by this paper
• The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).

  1990cited by this paper
• Duodenal pH in cystic fibrosis and its relationship to fat malabsorption

  1990cited by this paper
• Colorectal Liver Metastases: Is ‘No Treatment’ Still Best?

  1989cited by this paper
• Pathophysiology of the exocrine pancreas in cystic fibrosis.

  1989cited by this paper
• Pancreatic insufficiency in cystic fibrosis: result of defect in ontogenesis of the exocrine pancreas.

  1984cited by this paper
• Structural and developmental abnormalities of the exocrine pancreas in cystic fibrosis.

  1984cited by this paper
• Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption.

  1982cited by this paper
• Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency.

  1973cited by this paper
• Vitamin E.

  1959cited by this paper
• Modern Nutrition In Health And Disease

  1956cited by this paper
• Rapid method for the determination of fat in feces.

  1949cited by this paper
• CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE: A CLINICAL AND PATHOLOGIC STUDY

  1938cited by this paper

• Harm reduction in paediatric off-label therapy: ethical analysis of early CFTR modulator use in an infant with cystic fibrosis

  2026cites this paper
• Early Life Nutrition: The First 1000 Days and Healthy Aging in Cystic Fibrosis

  2026cites this paper
• The emerging role of pancreatic exocrine fibrosis as a common aetiological driver of islet dysfunction and diabetes: opportunities for novel disease-modifying interventions.

  2026cites this paper
• Social determinants of health, cystic fibrosis-related diabetes, and mental health in adult patients with cystic fibrosis: a critical synthesis of narrative review

  2026cites this paper
• Role of elexacaftor-tezacaftor-ivacaftor therapy on fecal elastase-1 and fat-soluble vitamins in children with cystic fibrosis

  2026influential citation
• Gastrointestinal Manifestations in Cystic Fibrosis

  2025cites this paper
• Impact of Elexacaftor-Tezacaftor-Ivacaftor on Gastrointestinal Symptoms, Intestinal Ultrasound, and Pancreatic Stiffness in Cystic Fibrosis

  2025cites this paper
• Generation of a pseudo-timeline describing progressive human exocrine and endocrine pancreatic pathology in cystic fibrosis through novel semi-quantitative scoring and AI-driven quantitative image analysis

  2025cites this paper
• Characterization of Egyptian Cystic Fibrosis children including genotypes and phenotypes: A Single Tertiary Center Experience.

  2025cites this paper
• Pancreatic Enzyme Replacement Therapy: Not Only in Chronic Pancreatitis.

  2025cites this paper
• Strength‐Oriented Virtual Exercise Training Intervention in Children and Adolescents with Cystic Fibrosis Under CFTR Modulators (the FIQMODE Study): Study Protocol for a Randomized Controlled Trial

  2025cites this paper
• Effectiveness of nutritional intervention package versus conventional nutritional counseling in pediatric cystic fibrosis: A randomized controlled trial.

  2025cites this paper
• МУКОВИСЦИДОЗ КАК КОМПЛЕКСНАЯ ПРОБЛЕМА ГЕНЕТИКИ, МИКРОБИОЛОГИИ, ПЕДИАТРИИ И ХИРУРГИИ

  2025cites this paper
• Diagnosis and Management of Exocrine Pancreatic Insufficiency

  2025cites this paper
• The endocrine complications of cystic fibrosis

  2025cites this paper
• Real-world safety of Symdeko: insights from the food and drug administration adverse event reporting system

  2025cites this paper
• Personalized Medicine in Cystic Fibrosis: Characterization of Eight Rare CFTR Variants in Intestinal Organoids and Cellular Models

  2025cites this paper
• Review of Disordered Eating Behaviors in Cystic Fibrosis

  2025cites this paper
• Evolution and Prognostic Variables of Cystic Fibrosis in Children and Young Adults: A Narrative Review

  2025cites this paper
• The State of Weight in Cystic Fibrosis: Understanding Nutritional Status and Individualizing Nutritional Care in the Modulator Era

  2025influential citation
• Pancreatic, nutritional and clinical outcomes in children 0–5 years with cystic fibrosis during the first 2 years of CFTR modulator therapy (PaNC): a multicentre prospective observational study protocol

  2025cites this paper
• Phenotypic diversity of cystic fibrosis:pathogenesis and modifying factors

  2025cites this paper
• Sweat testing and cystic fibrosis – Test performance before and after a quality improvement project in a South African tertiary hospital laboratory

  2025cites this paper
• Systemic in utero gene editing as a treatment for cystic fibrosis

  2025cites this paper
• A comprehensive review of gastrointestinal manifestations in cystic fibrosis in the era of highly effective modulator therapy.

  2025cites this paper
• Differential Expression and Microsystem Physiology Reveal Predominant and Drug Reversible CFTR-Related Defects in Idiopathic Pancreatitis

  2025cites this paper
• Risk of Pancreatic Cancer in Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Germline Variants: A Retrospective Cohort Study

  2025cites this paper
• Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.

  2025cites this paper
• Clinical and laboratory findings of patients with cystic fibrosis: a single center experience from Türkiye

  2025cites this paper
• Cystic fibrosis-related bone disease: an update on screening, diagnosis, and treatment

  2025cites this paper
• PPI and PERT for Exocrine Pancreatic Insufficiency—Pertinent or Problem?

  2025cites this paper
• Personalized therapy with CFTR modulators: Response of p.Ile148Asn variant.

  2025cites this paper
• Prevalence and characteristics of gastrointestinal disorders, medication use, and diagnostic interventions in pediatric patients with cystic fibrosis: a nested case–control analysis from the TriNetX EMR-derived global research network real-world dataset

  2025cites this paper
• Identification of a vimentin-expressing α-cell phenotype in CF and normal pancreas

  2025cites this paper
• Johanson–Blizzard syndrome caused by novel UBR1 mutation in four Saudi patients

  2024cites this paper
• Pathogenesis and symptomatic therapy of cystic fibrosis

  2024cites this paper
• European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidence‐based recommendations

  2024cites this paper
• Small molecules enhance the high-efficiency generation of pancreatic ductal organoids

  2024cites this paper
• Non pathological sweat test, pancreatic insufficiency and Cystic Fibrosis: an unusual case in a child with F508del-duplication of exons 1–3 CFTR genotype

  2024cites this paper
• Endocrine pathology in young rabbits with cystic fibrosis

  2024cites this paper
• A prospective mixed‐methods pilot study of a novel group structured education programme for adults with cystic fibrosis diabetes

  2024cites this paper
• Fibrosis quística y el virus SARS-CoV-2: una revisión

  2024cites this paper
• Patients with cystic fibrosis do not have an increased risk of adverse events after endoscopic retrograde cholangiopancreatography: a propensity-matched analysis

  2024cites this paper
• Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis

  2024cites this paper
• Exploring Therapeutic Strategies for Pediatric Cystic Fibrosis: An In-Depth Comparative Review

  2024cites this paper
• Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report

  2024cites this paper
• Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study.

  2024cites this paper
• Fluorescence lifetime imaging of human pancreatic lipase activity using a novel probe for early diagnosis of severe acute pancreatitis.

  2024cites this paper
• Cystic Fibrosis Related Diabetes: a first Canadian Clinical Practice guideline.

  2024cites this paper
• Systemic in utero gene editing as a treatment for cystic fibrosis

  2024cites this paper
• A review of proton pump inhibitor use in cystic fibrosis and considerations for deprescribing

  2024cites this paper
• Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2 Through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2, Open-Label Clinical Trial.

  2024cites this paper
• Retrospective Study Pre and Post Gastrostomy in Pediatric Patients with Cystic Fibrosis: Brazilian Multicenter Study

  2024cites this paper
• Testosterone concentrations and associated predictors in men with cystic fibrosis: a retrospective, single-center study.

  2024cites this paper
• Cystic fibrosis - diagnosis and treatment

  2024cites this paper
• Potential risk of porcine-derived pancreatic enzyme medication for the cross-species transmission of hepatitis E virus

  2024cites this paper
• Giving adolescents with cystic fibrosis a voice: Predicting cystic fibrosis nutritional adherence from their decision-making involvement.

  2024cites this paper
• In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets

  2024cites this paper
• Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor

  2024cites this paper
• Pancreatitis in cystic fibrosis: Presentation, medical and surgical management, and the impact of modulator therapies

  2024cites this paper
• Association of in‐line digestive enzyme cartridge with enteral feeds on improvement in anthropometrics among pediatric patients with cystic fibrosis

  2024cites this paper
• Recommended Tool Compounds for Modifying the Cystic Fibrosis Transmembrane Conductance Regulator Channel Variants.

  2024cites this paper
• Alterations in exocrine pancreatic function after acute pancreatitis

  2024cites this paper
• Early onset of abnormal glucose tolerance in patients with cystic fibrosis: A systematic review and meta-analysis.

  2024cites this paper
• Exocrine Pancreatic Insufficiency in Children – Challenges in Management

  2023cites this paper
• Low Vitamin K Status In Adults With Cystic Fibrosis Is Associated With Reduced Body Mass Index, Insulin Secretion And Increased Pseudomonal Colonization.

  2023cites this paper
• Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine

  2023cites this paper
• Cystic Fibrosis: Back to the Basics.

  2023cites this paper
• Nutritional Care in Children with Cystic Fibrosis

  2023cites this paper
• Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators

  2023cites this paper
• Nanomaterials for mRNA‐based therapeutics: Challenges and opportunities

  2023cites this paper
• Cystic fibrosis and primary ciliary dyskinesia: Similarities and differences.

  2023cites this paper
• Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO

  2023cites this paper
• Inherited causes of exocrine pancreatic insufficiency in pediatric patients: clinical presentation and laboratory testing

  2023cites this paper
• Genetic Modifiers of Cystic Fibrosis Lung Disease Severity: Whole Genome Analysis of 7,840 Patients.

  2023cites this paper
• Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial

  2023cites this paper
• Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and At Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.

  2023cites this paper
• Nutritional considerations for a new era: A CF foundation position paper.

  2023cites this paper
• Evaluation and management of exocrine pancreatic insufficiency: pearls and pitfalls

  2023cites this paper
• Cystic Fibrosis: A Review.

  2023cites this paper
• Approach to a Child with Chronic Diarrhea

  2023cites this paper
• Cystic Fibrosis-Associated Gastrointestinal Disease in Neonates.

  2023cites this paper
• Cystic fibrosis: comorbidity with other serious diseases

  2023cites this paper
• Cystic Fibrosis.

  2023cites this paper
• Pseudo-Bartter Syndrome in Patients with Cystic Fibrosis and Clinical Features

  2023cites this paper
• Genotype-phenotype correlation in siblings with cystic fibrosis

  2023cites this paper
• Changes of androgen and corticosterone metabolites excretion and conversion in cystic fibrosis

  2023cites this paper
• Update on Cystic Fibrosis in Pediatric Patients

  2023cites this paper
• Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis.

  2023cites this paper
• ATP12A Proton Pump as an Emerging Therapeutic Target in Cystic Fibrosis and Other Respiratory Diseases

  2023cites this paper
• Changes in fecal lipidome after treatment with ivacaftor without changes in microbiome or bile acids.

  2023cites this paper
• A Gastroenterologist’s Guide to Care Transitions in Cystic Fibrosis from Pediatrics to Adult Care

  2023cites this paper
• The Risk of Developing of Malnutrition and the Principles of Correction of Nutritional Status Disorders in Children with Cystic Fibrosis

  2023cites this paper
• Association between Dietary Intake and Faecal Microbiota in Children with Cystic Fibrosis

  2023cites this paper
• Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis

  2023cites this paper
• Standards for the care of people with cystic fibrosis; establishing and maintaining health.

  2023cites this paper
• Real world study on elexacaftor‐tezacaftor‐ivacaftor impact on cholesterol levels in adults with cystic fibrosis

  2023cites this paper
• Estimation of Incidence and Evaluation of Clinical and Paraclinical Features of Cystic Fibrosis: A Rare Disease in Kurdistan Province between 2010 and 2020

  2023cites this paper
• Abdominal Surgical Procedures in Adult Patients With Cystic Fibrosis: What Are the Risks?

  2022influential citation
• CFTR Modulators: Current Status and Evolving Knowledge

  2022cites this paper